US-based clinical-stage biopharmaceutical company SFA Therapeutics, Inc. announced on Wednesday that it has named Dr Ananda Gubbi, PhD as its new director of Biostatistics.
In the new role, Dr Gubbi is to direct biostatistics at the company to help it develop its drug candidates more effectively.
Dr Gubbi, a seasoned leader in biostatistics, has more than 25 years of experience in leading complex statistical analyses for preclinical and Phase one through Phase IV clinical studies. He has worked as a consultant for biostatistics in the pharmaceutical industry and at Slippery Rock University.
Previously, Dr Gubbi earlier served as the associate director, Biostatistics, at CPC Clinical Services, biostatistician at Amgen, Teva Pharmaceuticals, Kite Pharmaceuticals, Genentech, Sanofi-Aventis Pharmaceuticals, Schering-Plough, Pharmacia-Upjohn and Boehringer Ingelheim. He has also served as a statistical reviewer at the FDA where he developed his skillset in clinical trials.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval